Jhunjhunwala, Quadria likely to dilute stake in Concord IPO1 min read 06 Apr 2022, 01:16 AM IST
Concord Biotech is targeting an IPO of ₹2,000- ₹2,500 crore and plans to list within this calendar year
MUMBAI : Rakesh Jhunjunwala, healthcare-focused PE firm Quadria Capital, and other existing shareholders of Concord Biotech Ltd are likely to dilute part of their stakes in the company, as the active pharmaceutical ingredients (API) maker prepares for an initial public offering (IPO), said two people aware of the development.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started
Select your Category